SCHEMBL2818348

SCHEMBL2818348

Cc1cccc(N2CCN(C(=O)[C@@H]3C[C@H](NCc4cc(C(F)(F)F)cc(C(F)(F)F)c4)CN3Cc3ccccc3)CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 2/20 0.44
LMNA P02545 4/20 0.43
BCHE P06276 1/20 0.42
TEAD1 P28347 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTT P42858 2/20 0.41
KDM1A O60341 1/20 0.41
NPBWR1 P48145 1/20 0.41
MCHR1 Q99705 1/20 0.41
POLB P06746 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2818101 0.93 CHRM4 (0.52) CHRM4LMNATEAD1KMT2AHTT
SCHEMBL3638063 0.93 CHRM4 (0.52) CHRM4LMNATEAD1KMT2AHTT
SCHEMBL2819358 0.86 TACR1 (0.51) LMNABCHETEAD1KMT2AMEN1
SCHEMBL2817216 0.85 SIGMAR1 (0.48) BCHETEAD1CYP3A4USP2TACR1
SCHEMBL3638635 0.85 SIGMAR1 (0.48) BCHETEAD1CYP3A4USP2TACR1
SCHEMBL2817332 0.85 CHRM4 (0.53) CHRM4LMNAKMT2AHTTPOLB
SCHEMBL3641058 0.84 KMT2A (0.41) CHRM4LMNACYP3A4CYP2C9KMT2A
SCHEMBL2822473 0.84 KMT2A (0.41) CHRM4LMNACYP3A4CYP2C9KMT2A
SCHEMBL2820849 0.82 CHRM4 (0.47) CHRM4BCHETEAD1TACR1
SCHEMBL2818426 0.81 CHRM4 (0.49) CHRM4LMNABCHEKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155672-B1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-10-27 EP disclosed
US-7528136-B2 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS SLC6A3, OPRL1, OPRK1 CHRM4 1332/4885LMNA 4332/4885BCHE 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.